Cumberland Pharmaceuticals intends to file NDA with FDA for ifetroban in Duchenne muscular dystrophy cardiomyopathy

Cumberland Pharmaceuticals intends to file a New Drug Application with the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy.

Detected & updated continuously · Source: Nebula